TrialRheumatology (Oxford, England)2023

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.

Eduardo Mysler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.